Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Rhea-AI Summary
Anika (NASDAQ: ANIK) will release its fourth quarter and year-end 2025 financial results before market open on Thursday, February 26, 2026.
A conference call to discuss results and business highlights will follow at 8:30 a.m. ET. Investors can join via dial-in, a live audio webcast, and an archived presentation on Anika's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – ANIK
On the day this news was published, ANIK gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ANIK slipped 0.77% while peers were mixed: CTOR up 0.89%, CRDL down 1.85%, DERM down 1.84%, INCR down 0.49%, IRWD down 4.31%, indicating a stock-specific move around this scheduling update.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 results | Neutral | +2.3% | Reported Q3 2025 revenue decline with mixed channel performance and key milestones. |
| Oct 23 | Q3 results timing | Neutral | +3.7% | Announced Q3 2025 earnings release date and conference call details. |
| Jul 30 | Q2 2025 results | Negative | -27.4% | Q2 2025 revenue decline, adjusted outlook and continued losses from continuing operations. |
| Jul 16 | Q2 results timing | Neutral | +0.5% | Set Q2 2025 earnings release date and outlined access details for the call. |
| May 09 | Q1 2025 results | Negative | -21.0% | Q1 2025 total revenue decline, OEM weakness and updated 2025 guidance range. |
Earnings-related announcements, including simple scheduling releases, have generally seen price moves aligned with the underlying tone of the results, with negative earnings prints linked to double‑digit declines.
Across 2025, Anika’s earnings cycle combined pre-announcement scheduling releases with mixed fundamental results. Q1 and Q2 2025 showed revenue declines and guidance adjustments, leading to price drops of 21.03% and 27.42%, respectively. In contrast, Q3 2025 results with more balanced metrics saw a 2.28% gain, and the Q3 reporting-date announcement on Oct 23, 2025 produced a 3.73% rise. Today’s notice of Q4 and year-end 2025 timing fits this pattern of routine earnings-date communications preceding fuller financial disclosures.
Historical Comparison
In the past year ANIK issued 5 earnings‑tagged updates averaging a -8.4% move, with larger declines tied to weaker revenue and guidance versus more muted reactions to scheduling notices.
Earnings updates in 2025 tracked Q1–Q3 results and repeated pre-announcement notices. The new Q4 and full-year 2025 timing continues this cadence of scheduled disclosures following mixed but evolving channel trends and guidance refinements.
Market Pulse Summary
This announcement sets the schedule for Anika’s fourth quarter and year-end 2025 results, with a release before market open on February 26, 2026 and a call at 8:30 a.m. ET. In 2025, earnings updates produced sizable moves when revenue or guidance shifted, while simple timing notices saw more moderate reactions. Investors may focus on how Q4 data relate to earlier 2025 revenue declines, channel mix shifts, and any updated outlook once results are released.
AI-generated analysis. Not financial advice.
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
When will Anika (ANIK) report fourth quarter and year-end 2025 results?
What time is Anika's (ANIK) February 26, 2026 conference call?
How can investors access Anika (ANIK) earnings call dial-in and webcast?
Will Anika (ANIK) make the February 26, 2026 call recording available afterward?
Where can I find Anika (ANIK) presentation materials for the Q4 and year-end 2025 release?
